With Brexit looming and the UK PM Boris Johnson saying last week that we must prepare for ‘no deal’, the pharma industry is on tenterhooks.

Trade-deal details are still murky, and with new permits required for hauliers, the potential for backlogs affecting British ports is very likely. Not an ideal situation for cross-border operators, especially those that distribute refrigerated medicines, or worse, those getting drugs to patients that are in short supply.

Richard Torbett, Chief Executive of The Association of the British Pharmaceutical Industry (ABPI), summed up the mood on both sides of the English channel perfectly when he stated:

“No deal is not in the interest of patients, the pharmaceutical industry, or the economies of the UK and the EU.”

He continued by stressing something we must all hope for, saying “As long as a window of opportunity remains, negotiators must keep talking and agree to a comprehensive deal”.

The clock won’t stop counting, let’s hope that it’s not too late for a radical change of pace and more clearsightedness around the negotiating table.

Whatever the outcome, choosing a partner such as QUINTA-ANALYTICA with decades of global experience is more important now than ever before.

Stay up to date on all the industry news by following us on LinkedIn.

Additional News

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.

  • 3 October 2023

    Meet us at the heart of Pharma, CPHI 2023

    Quinta-Analytica is attending CPHI 2023 in Barcelona